BioSpace News Archive

Specifically, the civil subpoenas were issued to determine if the company had violated antitrust laws with its rheumatoid arthritis drug Remicade.

Teva Pharmaceuticals, Endo Pharmaceuticals and Taikoku Pharma entered into settlement agreements with the State of California for a total of almost $70 million. The settlements were over non-competitive, inter-company deals that prevented cheaper drugs from entering the market.

On July 18, it was reported by Reuters that Canada is opposed to any U.S. plans to buy Canadian prescription drugs because the country fears it will threaten its own drug supply or raise costs for its own people.

Medigene AG announced its participation at the following upcoming investor conferences:

Hutchison China MediTech Limited announces its unaudited financial results for the six months ended June 30, 2019 and provides updates on key clinical programs.

Fluidity One-W wins SLAS new product award for enabling in-solution interaction analysis of challenging proteins

TLC announced financial results for the second quarter ended June 30, 2019, and provided a business update.

There were two issues the agency had. First, the FDA wanted the inclusion of two animal studies to evaluate whether the drug caused thickening of the heart valve. The second was more of a goof—the contract research organization Zogenix employed uploaded the wrong data set for the application.

Biogen and Alkermes announced positive topline data from EVOLVE-MS-2, a Phase III trial of diroximel fumarate for relapsing-remitting multiple sclerosis compared to Tecfidera.

Auris Medical Holding Ltd., a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, announced that the first patient has been randomized in its “TRAVERS” Phase 2 trial of AM-125, the Company’s investigational drug for the treatment of acute vertigo.